Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: the phase II RACHEL study

被引：0
|
作者：
E Van Cutsem
C-P Li
E Nowara
G Aprile
M Moore
I Federowicz
J-L Van Laethem
C Hsu
C K Tham
S M Stemmer
R Lipp
A Zeaiter
A Fittipaldo
Z Csutor
B Klughammer
X Meng
T Ciuleanu
机构：
[1] Gastroenterology/Digestive Oncology,Division of Gastroenterology, Department of Medicine
[2] University Hospitals Leuven and KU Leuven,Department of Medical Oncology
[3] Taipei Veterans General Hospital,Division of Medical Oncology and Hematology
[4] National Yang-Ming University School of Medicine,Department of Gastroenterology
[5] Centrum Onkologii—Instytut im. Marii Skłodowskiej-Curie Oddział w Gliwicach,GI Cancer Unit
[6] ul. Wybrzeże Armii Krajowej 15,Department of Medical Oncology
[7] University Hospital of Udine,undefined
[8] Princess Margaret Hospital,undefined
[9] NZOZ Magodent,undefined
[10] Erasme University Hospital-ULB-Brussels,undefined
[11] National Taiwan University Hospital,undefined
[12] National Cancer Center Singapore,undefined
[13] Institute of Oncology,undefined
[14] Davidoff Center,undefined
[15] Rabin Medical Center,undefined
[16] GermanOncology GmbH,undefined
[17] Roche Products Ltd,undefined
[18] F. Hoffmann-La Roche,undefined
[19] PD Biostatistics,undefined
[20] Roche,undefined
[21] Institute of Oncology Ion Chiricuta and UMF Iuliu Hatieganu,undefined
来源：
British Journal of Cancer | 2014年 / 111卷
关键词：
pancreatic cancer; erlotinib; epidermal growth factor; oncology; dose; rash;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2067 / 2075
页数：8
相关论文
共 50 条
  • [1] Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: the phase II RACHEL study
    Van Cutsem, E.
    Li, C-P
    Nowara, E.
    Aprile, G.
    Moore, M.
    Federowicz, I.
    Van Laethem, J-L
    Hsu, C.
    Tham, C. K.
    Stemmer, S. M.
    Lipp, R.
    Zeaiter, A.
    Fittipaldo, A.
    Csutor, Z.
    Klughammer, B.
    Meng, X.
    Ciuleanu, T.
    BRITISH JOURNAL OF CANCER, 2014, 111 (11) : 2067 - 2075
  • [2] DOSE ESCALATION TO RASH FOR ERLOTINIB PLUS GEMCITABINE IN PATIENTS WITH METASTATIC PANCREATIC CANCER: THE PHASE II RACHEL (BO21128) STUDY
    Van Cutsem, Eric
    Nowara, Elzbieta
    Ciuleanu, Tudor
    Aprile, Giuseppe
    Moore, Malcolm
    Federowicz, Irena
    Van Laethem, Jean Luc
    Hsu, Chiun
    Ali, Sajid
    Csutor, Zsuzsanna
    Meng, Xianhua
    Li, Chung-Pin
    ANNALS OF ONCOLOGY, 2012, 23 : 6 - 7
  • [3] A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer
    Andrew H. Ko
    Alan P. Venook
    Emily K. Bergsland
    R. Kate Kelley
    W. Michael Korn
    Elizabeth Dito
    Brian Schillinger
    Janet Scott
    Jimmy Hwang
    Margaret A. Tempero
    Cancer Chemotherapy and Pharmacology, 2010, 66 : 1051 - 1057
  • [4] A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer
    Ko, Andrew H.
    Venook, Alan P.
    Bergsland, Emily K.
    Kelley, R. Kate
    Korn, W. Michael
    Dito, Elizabeth
    Schillinger, Brian
    Scott, Janet
    Hwang, Jimmy
    Tempero, Margaret A.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 66 (06) : 1051 - 1057
  • [5] A phase II study of erlotinib plus gemcitabine in Japanese patients with unresectable pancreatic cancer
    Nakachi, K.
    Okusaka, T. O.
    Funakoshi, A. F.
    Ioka, T. I.
    Yamao, K. Y.
    Ohkawa, S. O.
    Boku, N. B.
    Komatsu, Y. K.
    Nakamori, S. N.
    Furuse, J. F.
    EJC SUPPLEMENTS, 2009, 7 (02): : 387 - 387
  • [6] Phase II study of erlotinib plus gemcitabine in Japanese patients with unresectable pancreatic cancer
    Okusaka, Takuji
    Furuse, Junji
    Funakoshi, Akihiro
    Ioka, Tatsuya
    Yamao, Kenji
    Ohkawa, Shinichi
    Boku, Narikazu
    Komatsu, Yoshito
    Nakamori, Shoji
    Iguchi, Haruo
    Ito, Tetsuhide
    Nakagawa, Kazuhiko
    Nakachi, Kohei
    CANCER SCIENCE, 2011, 102 (02) : 425 - 431
  • [7] A phase II study of isoflavone, gemcitabine, and erlotinib in locally advanced (LA) or metastatic pancreatic cancer
    Hammad, N.
    Philip, P. A.
    Shields, A. F.
    Sarkar, F. H.
    Abruzzese, J. L.
    Kaseb, A. O.
    Javle, M. M.
    Varadhachary, G. R.
    Wolff, R. A.
    El-Rayes, B. F.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [8] A phase II study of bevacizumab (BEV) plus erlotinib (ERL) in patients with gemcitabine (GEM)-refractory metastatic pancreatic cancer (MPC)
    Ko, A. H.
    Dito, E.
    Schillinger, B.
    Venook, A. P.
    Bergsland, E. K.
    Korn, W. M.
    Tempero, M. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [9] Efficacy of gemcitabine plus erlotinib in rash-positive patients with metastatic pancreatic cancer selected according to eligibility for FOLFIRINOX: A prospective phase II study of the 'Arbeitsgemeinschaft Internistische Onkologie'
    Haas, M.
    Siveke, J. T.
    Schenk, M.
    Lerch, M. M.
    Caca, K.
    Freiberg-Richter, J.
    von Weikersthal, L. Fischer
    Kullmann, F.
    Reinacher-Schick, A.
    Fuchs, M.
    Kanzler, S.
    Kunzmann, V.
    Ettrich, T. J.
    Kruger, S.
    Westphalen, C. B.
    Held, S.
    Heinemann, V.
    Boeck, S.
    EUROPEAN JOURNAL OF CANCER, 2018, 94 : 95 - 103
  • [10] A phase II study of erlotinib in gemcitabine refractory advanced pancreatic cancer
    Renouf, D. J.
    Tang, P. A.
    Hedley, D.
    Chen, E.
    Kamel-Reid, S.
    Tsao, M. S.
    Tran-Thanh, D.
    Gill, S.
    Dhani, N.
    Au, H. J.
    Wang, L.
    Moore, M. J.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 (11) : 1909 - 1915
12345